0001428336-24-000002.txt : 20240108 0001428336-24-000002.hdr.sgml : 20240108 20240108090146 ACCESSION NUMBER: 0001428336-24-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 24518599 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20240108.htm 8-K hqy-20240108
0001428336false00014283362024-01-082024-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 8, 2024
HEALTHEQUITY, INC.

Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 7.01    Regulation FD Disclosure
On January 8, 2024, HealthEquity, Inc. (the "Company") issued a press release, attached as Exhibit 99.1 to this current report on Form 8-K, announcing its estimated year-end sales results for its fiscal year ending January 31, 2024 and that it will discuss these results and estimates, along with additional information regarding HSA cash maturities and capital allocation considerations, during its virtual presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 4:30 PM Pacific Time. An audio webcast of the presentation along with a copy of the Company's presentation material from the conference will be available through the investor page at the Company website: ir.healthequity.com.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
99.1
104
Cover Page Interactive Data File (formatted in Inline XBRL)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: January 8, 2024By:/s/ James Lucania
Name:James Lucania
Title:Executive Vice President and Chief Financial Officer



EX-99.1 2 jpmhccconf2024vf.htm EX-99.1 Document

image_0.jpg
HealthEquity Announces Year-End HSA Sales Outlook;
Presentation at J.P. Morgan Healthcare Conference; Investor Day

Draper, Utah – (GLOBE NEWSWIRE) – January 8, 2024 – HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced estimates of HSAs, HSA assets and total accounts for its fiscal year ending January 31, 2024, reflecting a strong sales year with new HSAs and custodial asset growth.
-Estimated HSAs to be approximately 8.7 million by January 31, 2024, up from 8.0 million a year earlier.
-Estimated HSA assets to be approximately $24.5 billion, up from $22.1 billion at the end of fiscal year 2023, with approximately $15 billion of HSA cash. Invested balances included in the estimated assets are subject to market fluctuation.
-Estimated total accounts to be approximately 15.6 million compared to 14.9 million at the end of fiscal year 2023.
These estimates do not include the BenefitWallet HSA portfolio acquisition that is expected to close in fiscal 2025.
Commenting on the results, Jon Kessler, President and CEO said, “Together with an integrated network of over 200 health and retirement plan partners, brokers and benefit advisors, Team Purple delivered strong new logo growth, opening approximately 900,000 new HSAs this year and providing a base for continued growth in FY25 and beyond.”
The Company also announced that it expects to beat its full-year goals for its Enhanced Rates offering, with over 30% of HSA cash assets expected to be in Enhanced Rates and a 40% increase in capacity with highly rated insurance partners in fiscal 2024. “The growth of Enhanced Rates is a win for our members and for HealthEquity,” said James Lucania, EVP and CFO. “We expect the continued growth of Enhanced Rates, along with favorable repricing of maturing HSA cash contracts, to create strong tailwinds over the next several years.”
HealthEquity will discuss these results and estimates during a presentation by Jon Kessler, President and CEO and James Lucania, EVP and CFO, at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 4:30 pm Pacific Time in the Elizabethan Room of the St. Francis Hotel.
An audio webcast of the presentation along with a copy of the presentation slides will be available and archived on HealthEquity’s investor relations website at http://ir.healthequity.com.
HealthEquity also announced the registration links for its investor day are now open for institutional investors and analysts. The February 22, 2024, investor day will be held at its corporate offices at 121 W. Scenic Pointe Drive, Draper, Utah from 8am to 1pm MT. Participants are encouraged to attend by registering at http://ir.healthequity.com. Management presentations, discussion panels and materials will be webcast and archived for those not able to attend the event in Draper, Utah.

About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 15 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our vision of saving and improving the lives of healthcare consumers. For more information, visit www.healthequity.com.



Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
our acquisition of the BenefitWallet HSA portfolio may not be consummated, and if consummated, we may not realize the expected benefits;
our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
the significant competition we face and may face in the future, including from those with greater resources than us;
our reliance on the availability and performance of our technology and communications systems;
potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
our reliance on partners and third-party vendors for distribution and important services;
our ability to develop and implement updated features for our technology platforms and communications systems; and
our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2023, our Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2023, and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.





Investor Relations Contact:
Richard Putnam
801-727-1000
rputnam@healthequity.com


EX-101.SCH 3 hqy-20240108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hqy-20240108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 hqy-20240108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover Page
Jan. 08, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 08, 2024
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
XML 8 hqy-20240108_htm.xml IDEA: XBRL DOCUMENT 0001428336 2024-01-08 2024-01-08 0001428336 false 8-K 2024-01-08 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20240108.htm hqy-20240108.xsd hqy-20240108_lab.xml hqy-20240108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hqy-20240108.htm": { "nsprefix": "hqy", "nsuri": "http://healthequity.com/20240108", "dts": { "inline": { "local": [ "hqy-20240108.htm" ] }, "schema": { "local": [ "hqy-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hqy-20240108_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20240108_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://healthequity.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240108.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240108.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001428336-24-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-24-000002-xbrl.zip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end